Comparative Pharmacology
Head-to-head clinical analysis: DRONEDARONE HYDROCHLORIDE versus SOTYLIZE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DRONEDARONE HYDROCHLORIDE versus SOTYLIZE.
DRONEDARONE HYDROCHLORIDE vs SOTYLIZE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dronedarone is a benzofuran derivative with antiarrhythmic properties belonging to class III. It blocks multiple ion channels (K+, Na+, Ca2+) and exhibits antiadrenergic effects. It prolongs atrial refractory periods and reduces ventricular rate.
Selective beta-1 adrenergic receptor antagonist; also exhibits class III antiarrhythmic activity (potassium channel blockade), prolonging cardiac repolarization and refractory periods.
400 mg orally twice daily with meals.
Initial: 80 mg orally twice daily. May increase every 2-3 days in 40-80 mg increments up to 240-320 mg/day. Maximum: 320 mg/day in divided doses.
None Documented
None Documented
Terminal half-life is approximately 24 hours (range 13–31 hours) after multiple dosing. Steady state is reached within 4–8 days. The prolonged half-life supports once-daily dosing but requires caution in renal impairment due to accumulation of inactive metabolites.
Terminal elimination half-life is 12-16 hours in patients with normal renal function; can extend up to 30-40 hours in renal impairment, requiring dose adjustment.
Approximately 6% of an oral dose is excreted unchanged in urine. The majority is eliminated as metabolites via biliary excretion into feces (84% of total radioactivity recovered in feces, 6% in urine).
Primarily renal excretion of unchanged drug; 85-90% eliminated unchanged in urine, with the remainder via feces (<5%) and minimal biliary excretion.
Category C
Category C
Antiarrhythmic
Antiarrhythmic